Agilent's appeal against Synthego added CRISPR guide-RNA technology to the 2025 Federal Circuit PTAB docket.
The appeal involved substantially similar final written decisions in related IPRs. The court's review focused on the Board record and whether the patentability determinations were supported under the applicable standard.
For life-sciences patent owners, CRISPR disputes remain high stakes because the market value sits at the intersection of platform tools, research inputs, and therapeutic development.
The practical takeaway is familiar but important: biotech sophistication does not change the appellate lens for Board findings, expert evidence, and obviousness record support.